(267 days)
Not Found
No
The summary describes a mechanical transfer set for compounding, with no mention of AI or ML capabilities. The "Mentions AI, DNN, or ML" field is explicitly "Not Found".
No
The device is described as an Apex Compounding System Transfer Set, intended for use in compounding ingredients into a final solution within a pharmacy environment. It is not designed to directly treat a patient or provide therapeutic benefit.
No
Explanation: The device description and intended use clearly state that the APEX Transfer Set is used for compounding ingredients into a final solution for administration, not for diagnosing any medical condition. It's a component of a compounding system.
No
The device description clearly outlines physical components like a valved manifold, source lines, luer lock connectors, pump tubing, and a final container connector. This indicates a hardware-based medical device, not a software-only one.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is clearly stated as providing a fluid path for compounding ingredients from multiple source containers into a final solution within a pharmacy setting. This is a process related to preparing medications for patient administration, not for diagnosing a condition or analyzing a sample from the human body.
- Device Description: The description details a system for transferring fluids between containers, not for analyzing biological samples or performing diagnostic tests.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting specific analytes, or providing diagnostic information.
IVD devices are specifically designed to be used in vitro (outside the body) to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device's function is entirely focused on the preparation of solutions for eventual administration, which is a different category of medical device.
N/A
Intended Use / Indications for Use
The APEX Transfer Set is intended to be used with the APEX Compounding System. The administration sets are to be used in a sterile compounding environment within a pharmacy to provide a fluid path for the compounding of ingredients from multiple source containers into a final solution.
Product codes
LHI, NEP
Device Description
The Apex Compounding System Transfer Set consists of a valved manifold with micro, macro and flex source lines. The proximal end of the source line consists of a luer lock connector which allows for connection to a transfer spike or connector depending upon the source container being used. The outlet tubing connects each valve, through the manifold body and consists of two sections of pump tubing just before ending at a final container connector, a luer adapter, to connect to a final container bag for eventual patient administration. There are 26 source lines on the manifold which correspond to the device's ability to support 26 source containers. Each individual line is labeled with a unique numeric identifier and barcode for traceability and scanning.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Sterile compounding environment within a pharmacy
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The proposed APEX Transfer sets were subjected to functional and performance testing to demonstrate that the sets perform as intended.
The following testing was performed on the subject device to the performance criteria listed or included in the referenced standard:
- Visual inspection - free of cracks, damage, kinked tubes, disconnected components, valves seated within 5% of alignment
- Leakage no bubbles observed at joints with 10 psi air pressure (positive pressure), vacuum . pressure shall not fall in 30s while applying 28 in Hg (negative pressure)
- Joint strength
- Static load tensile force (ISO 8536-4)
- Peak pull force joints shall be > 5 lbf pulled to failure at 14 in/min (7 lbf for macro pump tube joints)
- Valve torque micro valve torque shall not exceed 14.2 oz in, macro valve torque shall not exceed 42.5 oz in
- Vacuum test vacuum pressure shall not fall in 30s while applying 28 in Hg
- Occlusion test - bubbles shall be observed from end after applying 0.5 psi air pressure while immersed
- Luer gauging (ISO 594-2)
- . Barcode Scan - scan shall match human readable number
- Magnetic flux density - shall be > 40 Gauss at a distance of 0.28"
- Life cycle testing (Spallation and Particulate contamination) USP 788 after simulated use
- Biocompatibility (ISO 10993-1)
- Cytotoxicity (MEM Elution, ISO 10993-5)
- Delayed-type hypersensitivity (Guinea Pig Maximization, ISO 10993-10)
- Intracutaneous Reactivity (ISO 10993-10)
- Acute Systemic Toxicity (ISO 10993-11)
- Hemocompatibility (Hemolysis, ASTM F756, ISO 10993-4)
- Material-Mediated Pyrogenicity (Rabbit Pyrogen, USP , ISO 10993-11)
- Associate device (APEX Compounding System)
- Delivery accuracy
Dextrose 70% at 20-25°C shall be ± 10% at 0.2 mL, ± 3% above 1 mL. Dextrose 70% at 15-30℃ shall be ± 10% at 0.2 mL, ± 6% above 1 mL. Other solutions at 15-30°C shall be ± 10% at 0.2 mL, ± 3% above 1 mL. - Fit -set shall be able to be attached and removed with audible and tactile feedback and without damage to components
- Delivery accuracy
- Associate device (B. Braun Spikes and Fluid Connector, B. Braun Final Containers)
- Leakage
- Source lines - no bubbles observed at connections after applying air pressure while immersed, vacuum pressure shall not fall in 30s while applying 28 in He
- . Final container connector - no leakage when subjected to water pressure source of 20 psi
- Leakage
The following comparative testing was performed on the subject and predicate device:
- . Specific Gravity Interchange – mean concentration of unintended ingredient during compounding for the subject device shall be
§ 880.5440 Intravascular administration set.
(a)
Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.(b)
Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.
0
Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
August 25, 2017
B. Braun Medical Inc. Ms. Tracy Maddock Sr. Regulatory Affairs Specialist 901 Marcon Blvd. Allentown, Pennsylvania 18109
Re: K151423
Trade/Device Name: APEX Compounding System Transfer Set Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular administration set Regulatory Class: Class II Product Code: LHI. NEP Dated: January 13, 2016 Received: January 14, 2016
Dear Ms. Tracy Maddock:
This letter corrects our substantially equivalent letter of February 19, 2016.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Actinclude requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device comples with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply
1
with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely.
Michael J. Ryan -S
for Lori A. Wiggins, MPT, CLT Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K151423
Device Name
APEX Compounding System Transfer Set
Indications for Use (Describe)
The APEX Transfer Set is intended to be used with the APEX Compounding System. The administration sets are to be used in a sterile compounding environment within a pharmacy to provide a fluid path for the compounding of ingredients from multiple source containers into a final solution.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
3
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
| 5. 510(k) Summary | K151423 |
|---|---|
| SUBMITTER: | B. Braun Medical Inc. |
| 901 Marcon Boulevard | |
| Allentown, PA 18109-9341 | |
| 610-266-0500 | |
| Contact: Tracy Maddock, RAC | |
| Sr. Regulatory Affairs Specialist | |
| Phone: (610) 596-2545 | |
| Fax: (610) 266-4962 | |
| E-mail: Tracy.Maddock@bbraun.com | |
| DATE: | February 18, 2016 |
| DEVICE NAME: | APEX Compounding System Transfer Set |
| COMMON OR | |
| USUAL NAME: | IV Fluid Transfer Set |
| DEVICE | |
| CLASSIFICATION: | Class II per 21 CFR 880.5440 Intravascular administration set |
| Product Code: LHI, NEP | |
| Classification Panel: General Hospital | |
| PREDICATE DEVICE: | Exacta-Mix 2400 Compounding System Administration set, Baxa |
| Corporation K002705, Class II, LHI, 880.5440. |
DESCRIPTION:
The Apex Compounding System Transfer Set consists of a valved manifold with micro, macro and flex source lines. The proximal end of the source line consists of a luer lock connector which allows for connection to a transfer spike or connector depending upon the source container being used. The outlet tubing connects each valve, through the manifold body and consists of two sections of pump tubing just before ending at a final container connector, a luer adapter, to connect to a final container bag for eventual patient administration. There are 26 source lines on the manifold which correspond to the device's ability to support 26 source containers. Each individual line is labeled with a unique numeric identifier and barcode for traceability and scanning.
5
INDICATIONS FOR USE:
The APEX Transfer Set is intended to be used with the APEX Compounding System. The administration sets are to be used in a sterile compounding environment within a pharmacy to provide a fluid path for the compounding of ingredients from multiple source containers into a final solution.
SUBSTANTIAL EQUIVALENCE:
The APEX Compounding System Transfer Set is substantially equivalent to the Baxa Exacta-Mix 2400 Compounding System Administration Set (K002705).
Comparison of Technological Characteristics with the Predicate Device
The subject device has the same indications for use (to provide a fluid path for the compounding of ingredients from multiple source containers into a final solution) and the same principle of operation as the predicate device. The subject Transfer Set is similar in design with respect to components and materials of construction. Both devices are provided as sterile, nonpyrogenic, individually packaged devices to be used with their respective compounding devices.
A table summarizing the comparison between the APEX Transfer Set and the predicate device is provided below.
| SUBJECT DEVICE:
APEX COMPOUNDING SYSTEM TRANSFER SET | PREDICATE DEVICE:
EXACTA-MIX 2400 COMPOUNDING SYSTEM
ADMINISTRATION SET (K002705) | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| INDICATIONS FOR USE | | |
| The APEX Transfer Set is intended to be used
with the APEX Compounding System. The
administration sets are to be used in a sterile
compounding environment within a pharmacy to
provide a fluid path for the compounding of
ingredients from multiple source containers into a
final solution. | The Exacta-Mix 2400 compounding system
administration sets, manufactured by Baxa
Corporation, are ancillary devices used in
conjunction with the Exacta-Mix 2400 compound
device. The administration sets are used in the
pharmacy to provide the fluid path for multiple
source ingredients into one final solution. | |
| DESCRIPTION | | |
| Transfer set is a sterile, non-pyrogenic,
disposable, individually packaged device
designed to work in conjunction with the APEX
compounding system to quickly and accurately
compound multi-ingredient sterile solutions by
withdrawing requested amounts of source
ingredients from their containers in a user
specified sequence into a final container. | Transfer set is a sterile, non-pyrogenic, disposable,
individually packaged device designed to work in
conjunction with the Baxa EM-2400 compounding
system to quickly and accurately compound multi-
ingredient sterile solutions by withdrawing requested
amounts of source ingredients from their containers
in a user specified sequence into a final container. | |
| SUBJECT DEVICE:
APEX COMPOUNDING SYSTEM TRANSFER SET | PREDICATE DEVICE:
EXACTA-MIX 2400 COMPOUNDING SYSTEM
ADMINISTRATION SET (K002705) | |
| TECHNOLOGY | | |
| ✓ Twenty-six (26) inlet sources | ✓ Twenty- four (24) inlet sources | |
| ✓ Micro or macro volume fluid transfer | ✓ Micro or macro volume fluid transfer | |
| ✓ 25 L max use, micro side / 300 L max use, macro side | ✓ 150 L max use | |
| ✓ Set requires attachment of transfer spikes or connector | ✓ Set requires attachment of inlet tubing sets | |
| COMPONENTS AND MATERIALS | | |
| Manifold Body: Polycarbonate | Valve Set Body: Polycarbonate | |
| Valve: TPV | Valve Core: Santoprene | |
| Pump Tube: Silicone | Outlet Pump Tube: Silicone | |
| Final Container Adapter: ABS | Large-Bore Connector: ABS | |
| Final Container Adapter Cap: ABS | Connector Cap: HDPE | |
| Inlet Male Luer Lock Connector: ABS, Acrylic | Inlet Connector: ABS | |
| Connector Cap: HDPE | Cap: Polycarbonate | |
| Source Line Tubing: PVC | Inlet tubing: PVC | |
| | Outlet Connector: Thermoplastic Elastomer | |
| TESTING | | |
| Visual inspection Leakage Static Load Joint tensile strength Valve torque Associate device (Delivery accuracy, Specific gravity interchange, Leakage, Fit) Life cycle testing - Spallation and Particulate contamination | Vacuum Occlusion Luer gauging Barcode scan Magnetic flux density | Accuracy
Fluid/air Leakage
Precipitant |
| STERILIZATION | | |
| Method: Ethylene oxide (EO) | Method: Gamma | |
| Sterility Assurance Level (SAL): 10-6 | Sterility Assurance Level (SAL): 10-6 | |
6
The differences between the predicate device and the subject device include:
-
The subject device has pre-attached source lines with male luer lock connectors and barcoded flags indicating the line number. The predicate device consists of a valve set and separate inlet lines to be added by the user. Additionally, the user must attach barcode labels to the inlet lines.
7
-
The subject device contains twenty-six (26) source lines giving the user the ability to compound solutions using 26 source containers. The predicate device has the potential for twenty-four (24) source lines.
-
The subject device and the predicate device allow the compounding of both micro and macro volumes. The predicate device has one fluid channel through the valve set. The subject device has two (2) channels, a micro channel and a macro channel.
-
The sterilization method for the subject device is ethylene oxide whereas the sterilization method for the predicate device is gamma irradiation.
The differences, between subject device and predicate device, do not raise any new issues of safety and effectiveness.
Performance Testing
The proposed APEX Transfer sets were subjected to functional and performance testing to demonstrate that the sets perform as intended.
The following testing was performed on the subject device to the performance criteria listed or included in the referenced standard.
- Visual inspection - free of cracks, damage, kinked tubes, disconnected components, valves seated within 5% of alignment
- Leakage no bubbles observed at joints with 10 psi air pressure (positive pressure), vacuum . pressure shall not fall in 30s while applying 28 in Hg (negative pressure)
- Joint strength
- Static load tensile force (ISO 8536-4) O
- Peak pull force joints shall be > 5 lbf pulled to failure at 14 in/min (7 lbf for macro O pump tube joints)
- Valve torque micro valve torque shall not exceed 14.2 oz in, macro valve torque shall not ● exceed 42.5 oz in
- Vacuum test vacuum pressure shall not fall in 30s while applying 28 in Hg ●
- Occlusion test - bubbles shall be observed from end after applying 0.5 psi air pressure while immersed
- Luer gauging (ISO 594-2) ●
- . Barcode Scan - scan shall match human readable number
- Magnetic flux density - shall be > 40 Gauss at a distance of 0.28"
- Life cycle testing (Spallation and Particulate contamination) USP 788 after simulated use ●
- Biocompatibility (ISO 10993-1)
- Cytotoxicity (MEM Elution, ISO 10993-5) O
- Delayed-type hypersensitivity (Guinea Pig Maximization, ISO 10993-10) O
- Intracutaneous Reactivity (ISO 10993-10) O
- Acute Systemic Toxicity (ISO 10993-11) O
- Hemocompatibility (Hemolysis, ASTM F756, ISO 10993-4) O
8
- Material-Mediated Pyrogenicity (Rabbit Pyrogen, USP , ISO 10993-11) o
- Associate device (APEX Compounding System) ●
- Delivery accuracy o
Dextrose 70% at 20-25°C shall be ± 10% at 0.2 mL, ± 3% above 1 mL. Dextrose 70% at 15-30℃ shall be ± 10% at 0.2 mL, ± 6% above 1 mL. Other solutions at 15-30°C shall be ± 10% at 0.2 mL, ± 3% above 1 mL.
- Fit -set shall be able to be attached and removed with audible and tactile feedback o and without damage to components
- Associate device (B. Braun Spikes and Fluid Connector, B. Braun Final Containers) ●
- Leakage o
- Source lines - no bubbles observed at connections after applying air pressure while immersed, vacuum pressure shall not fall in 30s while applying 28 in He
- . Final container connector - no leakage when subjected to water pressure source of 20 psi
- Leakage o
The following comparative testing was performed on the subject and predicate device:
- . Specific Gravity Interchange – mean concentration of unintended ingredient during compounding for the subject device shall be